ATRICURE INC (ATRC)
Health Care · medical devices · NASDAQ
AtriCure provides specialized surgical solutions and cryotherapy devices for the treatment of atrial fibrillation and the management of post-operative pain.
What ATRICURE INC does
AtriCure is a medical device company that develops surgical therapies and products for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its portfolio includes cardiac ablation devices for open-heart and minimally invasive surgical procedures, as well as cryotherapy-based nerve block probes to provide temporary relief from post-operative pain. The company sells its products globally to medical centers through both direct sales forces and international distributors.
Themes: atrial fibrillation (Afib) therapy, cardiac surgery, pain management, electrophysiology, minimally invasive surgery
Fundamentals
- Price$52.84 as of 2026-10-08 close
- Market cap$2.7B as of 2026-07-22 (share count; price 2026-10-08)
- 1-year return+50.6% 2025-10-08 close $35.08 → 2026-10-08 close $52.84
- P/E244.18 as of 2026-10-08
- Net margin-2.1% FY2025, SEC XBRL
- Gross margin+75.0% FY2025, SEC XBRL
- ROE-2.3% FY2025, SEC XBRL
- Debt / equity0.13 as of 2026-09-03
- Revenue growth (YoY)+13.9% as of 2026-09-03
- Revenue CAGR (3y)+17.4% SEC XBRL
- Beta0.89 as of 2026-09-03
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
How ATRC compares in its sector
- price-to-earnings ratiotop 10% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ATRC is not currently in any published Top 10 list. Its scores are below.
Top 10 score
43.6 #1058 of 1,379 scored · #123 of 151 in Health Care
Growth 72nd (3-year revenue CAGR 17.4%, revenue growth year over year 13.9%) and financial health 63rd (debt to equity 0.1, free cash flow margin 9%); weakest is profitability (15th, operating margin -1.8%, return on equity -2.3%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How ATRICURE INC looks technically
ATRICURE INC (ATRC) is trading 43.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 39 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-09-04, breaking below its recent trading range. Trading volume is unusually light — only about 42% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 43.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +43.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $50.37 | $50.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $36.80 | $36.80 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 39 trading days ago — a "golden cross", a bullish long-term signal | 39 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with sellers in control | 38.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 45.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($51.63 to $61.70) — its "stochastic" reading is 12 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 12.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $61.70 | $61.70 |
|---|---|---|
| From the 52-week high | it is 14.4% below its 52-week high (its highest price of the past year) | -14.4% |
| Above the 52-week low | it is 108.3% above its 52-week low (its lowest price of the past year) | +108.3% |
| Below the 52-week high | it is 14.4% below its highest point of the past year | 14.4% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-09-04, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $89.18 (set on 2021-11-05) | $89.18 |
| Given back of the 52-week move | over the past year its closes ranged ($25.86 to $60.77), and it has given back roughly a quarter of its rise from last year’s low — 23% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $38.08 to $39.20. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.7% |
| From the all-time high | it is 40.7% below its all-time high | -40.8% |
| Nearest price level | it is trading 18.8% above a support level at $42.89 — a price it turned at four times since 2025-01-29, most recently on 2026-01-08. Since 2024-10-08 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -18.8% |
| All-time low | its lowest closing price on record is $1.00 (set on 2009-04-24) | $1.00 |
| Above the all-time low | it is 5184.0% above its all-time low | +5,184% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 46th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.39 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.39 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $52.19 and $61.29 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $52.19 – $56.74 – $61.29 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 6.7 daily ranges above its 200-day average price (43.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 42% of its 30-day average | 0.42× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.9% since the prior reading | +2.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.20 toward sell |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 5.4% above the previous close 22 sessions ago and has not traded back through the level it left behind at 51.52 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.4% |
| Gap filled | a 2.0% gap down opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.26% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.7 percentage points (the stock lost 1.7% while the market gained 1.0%) | -2.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 53.2 percentage points (the stock gained 57.0% while the market gained 3.8%) | +53.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 63.6 percentage points (the stock gained 81.0% while the market gained 17.5%) | +63.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 35.6 percentage points (the stock gained 50.6% while the market gained 15.0%) | +35.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 14.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +14.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 37% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $38.64 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +36.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-07-23 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $50.92 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +3.8% |
Price levels it has turned at before
ATRC last closed at $52.84 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $42.89 | Support | 18.8% below the last close | turned there four times · 2025-01-29 to 2026-01-08 |
| $38.79 | Support | 26.6% below the last close | turned there twice · 2025-02-03 to 2026-01-02 |
| $38.08 | Support | 27.9% below the last close | turned there 8 times · 2024-11-11 to 2025-10-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · Analyst price target recently RAISED · beating the market · Stretched far above its 200-day average (6+ daily ranges) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.90 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$54.89 range $36.00 – $65.00; median $55.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ATRC
- Consensus EPS estimate$0.01192 next reporting period, as of 2026-10-06
- Estimate change, 30 days$0.00 from $0.01192, on 2026-09-01, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Difficulty of treating Afib and variability in long-term procedural success.","Dependence on medical centers adopting surgical and hybrid ablation procedures.","Risks associated with international distribution and currency fluctuations."]
What changed in the latest 10-Q
AI-assisted comparison of ATRC's 10-Q filed 2026-07-27 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- Newer filing (2026-07-27) states in Item 5 that during the three months ended June 30, 2026, none of the executive officers or directors adopted, terminated or modified a trading arrangement, with no exceptions.
- Newer filing (2026-07-27) includes Exhibit 10.1 for AtriCure, Inc. 2023 Stock Incentive Plan (Amended and Restated as of May 18, 2026), incorporated by reference to Form 8-K filed on May 19, 2026.
- Newer filing (2026-07-27) includes Exhibit 10.2 for AtriCure, Inc. 2018 Employee Stock Purchase Plan (Amended and Restated as of May 18, 2026), incorporated by reference to Form 8-K filed on May 19, 2026.
- Removed:
- Older filing (2026-05-06) included in Item 5 a description of Salvatore Privitera, Chief Technical Officer, adopting a Rule 10b5-1(c) trading plan on February 20, 2026 covering the sale of up to 24,343 shares between May 22, 2026 and February 19, 2027, which is absent from the newer filing.
- Older filing (2026-05-06) included Exhibit 10.1 for Form of Performance Share Award Agreement for Awards Granted in 2026, which is absent from the newer filing.
- Older filing (2026-05-06) included Exhibit 10.2 for First Amendment to Credit Agreement among JPMorgan Chase Bank, N.A. and AtriCure, Inc. dated January 9, 2026, which is absent from the newer filing.
- Reworded:
- Risk Factors section text is identical in both filings for the six quarters presented.
- Newer filing (2026-07-27) changes the reporting period in Item 5 from 'three months ended March 31, 2026' to 'three months ended June 30, 2026'.
- Newer filing (2026-07-27) removes the 'except as described below' phrase and subsequent trading plan description from Item 5.
- Signatures and dates changed from May 6, 2026 in the older filing to July 27, 2026 in the newer filing.
- Notes:
- Only the 'Item 1A Risk Factors' and continuing section text provided were compared; the exhibit list, signatures, and Item 5 sections are included because they appeared in the supplied source excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($559211) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 10 sells ($3M) — 8 selling insiders
- Last 180 days · read to 2026-10-040 buys · 12 sells ($4M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-23. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ATRC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for ATRC from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding ATRC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 7,058,979
- Reported value $197,553,586
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ATRC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ATRC had 4,279,518 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ATRC had 8.41% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.62 days to cover at the same settlement.
- Reported short interest (shares) 4,279,518
- Short interest (% of shares outstanding) 8.41%
- Prior settlement (shares) 4,141,306
- Reported change 3.34%
- Days to cover (reported) 3.62
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ATRC vs…
ATRICURE INC is found in…
Frequently asked questions
What does ATRICURE INC (ATRC) do?
AtriCure is a medical device company that develops surgical therapies and products for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its portfolio includes cardiac ablation devices for open-heart and minimally invasive surgical procedures, as well as cryotherapy-based nerve block probes to provide temporary relief from post-operative pain.
What sector is ATRICURE INC (ATRC) in?
ATRICURE INC (ATRC) is classified in the Health Care sector. Its industry is medical devices. It trades on NASDAQ.
Who are ATRICURE INC's (ATRC) competitors?
Notable peers of ATRICURE INC (ATRC) include Medtronic, Abbott Laboratories, Boston Scientific and Johnson & Johnson. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ATRC?
Yes — we hold 3 matched STOCK Act disclosures for ATRC from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ATRICURE INC (ATRC) overbought or oversold right now?
ATRICURE INC (ATRC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ATRC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.